Starting from a hit identified by focused screening, 3-aminopyrrolidine factor Xa inhibitors were designed. The binding mode as determined by X-ray structural analysis as well as the pharmacokinetic behaviour of selected compounds is discussed.
Organizational Affiliation: 
F Hoffmann - La Roche Ltd, Basel, Switzerland. katrin.groebke_zbinden@roche.com